ADC-118

N/A

Report date: 2025/12/23 14:20:25
NME

Base Information

Drug NameADC-118
Drug Alias NameAsuptegravir/Emtricitabine/Tenofovir AlafenamideADC-118ACC017/FTC/TAF
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes AsuptegravirEmtricitabineTenofovir Alafenamide Fumarate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Aidea Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Aidi Medical Technology Co Ltd
Inactive CompaniesJiangsu Aidea Pharmaceutical Group Co Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A